NASDAQ:ALKS Alkermes (ALKS) Stock Price, News & Analysis → The only AI company you should be looking at (From Behind the Markets) (Ad) Free ALKS Stock Alerts $27.53 -1.22 (-4.24%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$27.48▼$28.7950-Day Range$26.40▼$32.5652-Week Range$22.01▼$33.71Volume2.26 million shsAverage Volume1.95 million shsMarket Capitalization$4.60 billionP/E Ratio13.30Dividend YieldN/APrice Target$32.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Alkermes alerts: Email Address Alkermes MarketRank™ Stock AnalysisAnalyst RatingHold2.38 Rating ScoreUpside/Downside18.1% Upside$32.50 Price TargetShort InterestBearish7.79% of Shares Sold ShortDividend StrengthN/ASustainability-1.17Upright™ Environmental ScoreNews Sentiment0.99Based on 9 Articles This WeekInsider TradingSelling Shares$292,718 Sold Last QuarterProj. Earnings Growth-7.59%From $2.24 to $2.07 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.57 out of 5 starsMedical Sector327th out of 947 stocksPharmaceutical Preparations Industry156th out of 435 stocks 2.2 Analyst's Opinion Consensus RatingAlkermes has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 4 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.50, Alkermes has a forecasted upside of 18.1% from its current price of $27.53.Amount of Analyst CoverageAlkermes has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.79% of the outstanding shares of Alkermes have been sold short.Short Interest Ratio / Days to CoverAlkermes has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Alkermes has recently increased by 6.55%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlkermes does not currently pay a dividend.Dividend GrowthAlkermes does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlkermes has received a 60.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for physical health", "Antipsychotics", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Alkermes is -1.17. Previous Next 3.3 News and Social Media Coverage News SentimentAlkermes has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Alkermes this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for ALKS on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.MarketBeat Follows6 people have added Alkermes to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alkermes insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $292,718.00 in company stock.Percentage Held by InsidersOnly 4.76% of the stock of Alkermes is held by insiders.Percentage Held by Institutions95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Alkermes are expected to decrease by -7.59% in the coming year, from $2.24 to $2.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alkermes is 13.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 152.48.Price to Earnings Ratio vs. SectorThe P/E ratio of Alkermes is 13.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 225.29.Price to Book Value per Share RatioAlkermes has a P/B Ratio of 3.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Bull ReportThe AI Bottleneck No One is Talking AboutRenewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.Click here to see who's preparing to meet these needs About Alkermes Stock (NASDAQ:ALKS)Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Read More ALKS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALKS Stock News HeadlinesMarch 18, 2024 | finance.yahoo.comInsider Sell: SVP, Chief Commercial Officer Christian Nichols Sells Shares of Alkermes PLC (ALKS)March 18, 2024 | americanbankingnews.comShort Interest in Alkermes plc (NASDAQ:ALKS) Expands By 6.5%March 19, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.March 15, 2024 | nasdaq.comALKS Factor-Based Stock AnalysisMarch 15, 2024 | finance.yahoo.comAlkermes (ALKS) Stock Moves -0.45%: What You Should KnowMarch 11, 2024 | americanbankingnews.comAlkermes plc (NASDAQ:ALKS) Given Consensus Rating of "Hold" by AnalystsMarch 7, 2024 | finanznachrichten.deAlkermes plc: Alkermes Announces Appointment of Nancy S. Lurker to Board of DirectorsMarch 7, 2024 | finance.yahoo.comAlkermes Announces Appointment of Nancy S. Lurker to Board of DirectorsMarch 19, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:February 27, 2024 | stocknews.comTop 3 Biotech Stocks to Consider for March ProfitsFebruary 21, 2024 | msn.comUBS Downgrades Alkermes (ALKS)February 21, 2024 | finance.yahoo.comWhy Alkermes (ALKS) is a Top Growth Stock for the Long-TermFebruary 21, 2024 | investorplace.comWall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024February 20, 2024 | msn.comAlkermes downgraded at UBS as stock nears 52-week highFebruary 20, 2024 | markets.businessinsider.comZealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial resultsFebruary 17, 2024 | finance.yahoo.comALKS Mar 2024 32.000 callFebruary 17, 2024 | finance.yahoo.comAlkermes Full Year 2023 Earnings: Beats ExpectationsFebruary 16, 2024 | markets.businessinsider.comAlkermes: Hold Rating Affirmed Amid EBITDA Growth and Strategic Acquisitions, Balanced by Cautious Sales OutlookFebruary 16, 2024 | finance.yahoo.comAlkermes plc (NASDAQ:ALKS) Q4 2023 Earnings Call TranscriptFebruary 16, 2024 | markets.businessinsider.comAlkermes: A Strong Buy on Path to Profitability, Strategic Capital Allocation, and Pipeline MomentumFebruary 15, 2024 | finance.yahoo.comAlkermes' (ALKS) Q4 Earnings & Revenues Surpass EstimatesFebruary 15, 2024 | seekingalpha.comAlkermes plc 2023 Q4 - Results - Earnings Call PresentationFebruary 15, 2024 | finance.yahoo.comCompared to Estimates, Alkermes (ALKS) Q4 Earnings: A Look at Key MetricsFebruary 15, 2024 | markets.businessinsider.comAlkermes plc Q4 Earnings SummaryFebruary 15, 2024 | finance.yahoo.comIs Alkermes plc's (NASDAQ:ALKS) Recent Stock Performance Tethered To Its Strong Fundamentals?February 15, 2024 | finance.yahoo.comAlkermes PLC (ALKS) Reports Strong 2023 Financial Results and Sets Positive Outlook for 2024February 15, 2024 | finance.yahoo.comAlkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024See More Headlines Receive ALKS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today3/18/2024Next Earnings (Estimated)4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALKS CUSIPG0176710 CIK1520262 Webwww.alkermes.com Phone(531) 772-8000Fax781-890-0524Employees2,100Year Founded1987Price Target and Rating Average Stock Price Target$32.50 High Stock Price Target$39.00 Low Stock Price Target$25.00 Potential Upside/Downside+17.6%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$2.07 Trailing P/E Ratio13.35 Forward P/E Ratio12.33 P/E GrowthN/ANet Income$355.76 million Net Margins21.39% Pretax Margin25.34% Return on Equity16.10% Return on Assets9.15% Debt Debt-to-Equity Ratio0.24 Current Ratio2.86 Quick Ratio2.50 Sales & Book Value Annual Sales$1.66 billion Price / Sales2.78 Cash Flow$2.17 per share Price / Cash Flow12.73 Book Value$7.21 per share Price / Book3.83Miscellaneous Outstanding Shares167,080,000Free Float159,123,000Market Cap$4.62 billion OptionableOptionable Beta0.57 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Richard F. Pops (Age 62)Chairman & CEO Comp: $2.3MMr. Blair C. Jackson (Age 51)Interim Principal Financial Officer, Executive VP & COO Comp: $1.05MMr. David Joseph Gaffin (Age 52)Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary Comp: $1.08MMr. Iain Michael Brown (Age 55)Senior VP & CFO (Leave of Absence) Comp: $867.75kDr. Craig C. Hopkinson M.D. (Age 56)Executive VP of Research & Development and Chief Medical Officer Comp: $1.12MDr. Floyd E. Bloom M.D. (Age 87)Founder Comp: $57.73kMr. Samuel J. Parisi (Age 49)Interim Principal Accounting Officer & VP of Finance Mr. Thomas HarveyChief Information Officer & Senior VP of ITMs. Sandra CoombsSenior Vice President of Corporate Affairs & Investor RelationsMr. Michael J. Landine (Age 70)Senior VP of Corporate Development & Chief Risk Officer Comp: $750.46kMore ExecutivesKey CompetitorsEidos TherapeuticsNASDAQ:EIDXMadrigal PharmaceuticalsNASDAQ:MDGLAmicus TherapeuticsNASDAQ:FOLDIonis PharmaceuticalsNASDAQ:IONSAgios PharmaceuticalsNASDAQ:AGIOView All CompetitorsInsiders & InstitutionsChristian Todd NicholsSold 10,417 sharesTotal: $292,717.70 ($28.10/share)Vanguard Group Inc.Bought 2,288,185 shares on 3/11/2024Ownership: 12.542%Wellington Management Group LLPBought 3,494,678 shares on 3/5/2024Ownership: 9.122%Twin Focus Capital Partners LLCBought 80,032 shares on 3/5/2024Ownership: 0.048%Fisher Asset Management LLCBought 572 shares on 3/5/2024Ownership: 0.036%View All Insider TransactionsView All Institutional Transactions ALKS Stock Analysis - Frequently Asked Questions Should I buy or sell Alkermes stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ALKS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALKS, but not buy additional shares or sell existing shares. View ALKS analyst ratings or view top-rated stocks. What is Alkermes' stock price target for 2024? 8 Wall Street analysts have issued 12-month price targets for Alkermes' shares. Their ALKS share price targets range from $25.00 to $39.00. On average, they predict the company's share price to reach $32.50 in the next year. This suggests a possible upside of 18.1% from the stock's current price. View analysts price targets for ALKS or view top-rated stocks among Wall Street analysts. How have ALKS shares performed in 2024? Alkermes' stock was trading at $27.74 at the beginning of the year. Since then, ALKS stock has decreased by 0.8% and is now trading at $27.53. View the best growth stocks for 2024 here. Are investors shorting Alkermes? Alkermes saw a increase in short interest during the month of February. As of February 29th, there was short interest totaling 13,020,000 shares, an increase of 6.5% from the February 14th total of 12,220,000 shares. Based on an average daily volume of 2,330,000 shares, the days-to-cover ratio is currently 5.6 days. View Alkermes' Short Interest. When is Alkermes' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024. View our ALKS earnings forecast. How were Alkermes' earnings last quarter? Alkermes plc (NASDAQ:ALKS) issued its earnings results on Thursday, February, 15th. The company reported $0.22 EPS for the quarter, missing analysts' consensus estimates of $0.51 by $0.29. The business earned $377.50 million during the quarter, compared to analyst estimates of $362.78 million. Alkermes had a net margin of 21.39% and a trailing twelve-month return on equity of 16.10%. The company's revenue for the quarter was up 23.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.02) earnings per share. What ETFs hold Alkermes' stock? ETFs with the largest weight of Alkermes (NASDAQ:ALKS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Subversive Mental Health ETF (SANE), iShares Neuroscience and Healthcare ETF (IBRN), Horizon Kinetics Medical ETF (MEDX), ALPS Medical Breakthroughs ETF (SBIO), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE) and Putnam BioRevolution ETF (SYNB). How will Alkermes' stock buyback program work? Alkermes declared that its Board of Directors has approved a stock repurchase plan on Thursday, February 15th 2024, which allows the company to repurchase $400,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to purchase up to 8.2% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's management believes its shares are undervalued. What guidance has Alkermes issued on next quarter's earnings? Alkermes issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share guidance of 2.800-2.800 for the period, compared to the consensus estimate of 2.520. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.5 billion. What is Richard F. Pops' approval rating as Alkermes' CEO? 119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees. What other stocks do shareholders of Alkermes own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA). Who are Alkermes' major shareholders? Alkermes' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (12.56%), Vanguard Group Inc. (12.54%), Wellington Management Group LLP (9.12%), Hardman Johnston Global Advisors LLC (3.28%), RTW Investments LP (2.34%) and Primecap Management Co. CA (2.14%). Insiders that own company stock include Blair Curtis Jackson, Cato T Laurencin, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Richard F Pops, Shane Cooke and Wendy L Dixon. View institutional ownership trends. How do I buy shares of Alkermes? Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Alkermes have any subsidiaries? The following companies are subsidiares of Alkermes: Rodin Therapeutics.Read More This page (NASDAQ:ALKS) was last updated on 3/19/2024 by MarketBeat.com Staff From Our Partners8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.